Neurol. praxi 2017; 18(Suppl F): 5-8 | DOI: 10.36290/neu.2017.122
Cladribine – mechanism of action
- Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN, Praha
Cladribine represents a novel possibility of multiple sclerosis treatment. Mechanism of action is derived from observation of adenosindeaminase deficiency in severe combined immunodeficit. Cladribin exerts incomplete depletion of both activated and restingT- and B- lymphocytes, with repopulation which induces long-term shift in immune system function including change in cytokineproduction. When this effect is compared with alemtuzumab we observe difference in repopulation of B lymphocytes which donot jump above baseline values in patients treated with cladribine. This may explain no occurence of secondary autoimmunities.
Keywords: cladribine, multiple sclerosis, T- and B- lymphocytes
Published: December 1, 2017 Show citation
References
- Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017; 4(4): e360.
Go to original source... 
Go to PubMed... - Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand. 2004; 109(6): 390-392. Go to original source... Go to PubMed...
- Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93: 1716-1720. Go to original source... Go to PubMed...
- De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2017 Jan 1: 1352458517690269. Go to original source... Go to PubMed...
- Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 416-426. Go to original source... Go to PubMed...
- Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit. 2001; 7(1): 93-98. Go to PubMed...
- Kopadze T, Döbert M, Leussink VI, Dehmel T, Kieseier BC. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol. 2009; 16(3): 409-412. Go to original source... Go to PubMed...
- Korsen M, Bragado Alonso S, Peix L, Bröker BM, Dressel A. Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS One. 2015: 10(6). Go to original source...
- Kraus SH, Luessi F, Trinschek B, Lerch S, Hubo M, Poisa-Beiro L, Paterka M, Jonuleit H, Zipp F, Jolivel V. Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. Int Immunopharmacol. 2014; 18(2): 347-357. Go to original source... Go to PubMed...
- Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011; 34: 28-35. Go to original source... Go to PubMed...
- Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Soelberg S?rensen P, Vermersch P, Chang P, Hamlett A, Viglietta V, Musch B, Greenberg S. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler. 2009; 15: S248-S249. Abstract P816.
- Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010; 116(16): 2884-96. Go to original source... Go to PubMed...
- Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13. Go to original source... Go to PubMed...
- Soelberg-S?rensen P, Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Vermersch P, Bock D, Hamlett A, Fevr T, Musch B, Greenberg S. Effects of cladribine tablets on circulating lymphocyte subsets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis. ENS 2010 [P442].
- Soelberg-S?rensen P, Dangond F, Hicking C, Giobannoni G. Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension. Presented at European Charcot Foundation (ECF) 2016; November 24-28, 2016; Baveno, Italy. Go to original source...